Last reviewed · How we verify
Polymyxin e
Polymyxin E (colistin) disrupts bacterial cell membranes by binding to lipopolysaccharides and phospholipids, causing cell lysis and death.
Polymyxin E (colistin) disrupts bacterial cell membranes by binding to lipopolysaccharides and phospholipids, causing cell lysis and death. Used for Serious infections caused by multidrug-resistant gram-negative bacteria (e.g., Pseudomonas aeruginosa, Acinetobacter baumannii), Cystic fibrosis-associated respiratory infections.
At a glance
| Generic name | Polymyxin e |
|---|---|
| Also known as | Colistin |
| Sponsor | Mahmoud I Mostafa |
| Drug class | Polymyxin antibiotic |
| Target | Bacterial lipopolysaccharides and phospholipids |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Polymyxin E is a cyclic polypeptide antibiotic that acts as a cationic surfactant, penetrating and destabilizing the outer and inner membranes of gram-negative bacteria. It is bactericidal and particularly effective against multidrug-resistant gram-negative organisms. Due to its nephrotoxicity and neurotoxicity, it is typically reserved for serious infections caused by bacteria resistant to other antibiotics.
Approved indications
- Serious infections caused by multidrug-resistant gram-negative bacteria (e.g., Pseudomonas aeruginosa, Acinetobacter baumannii)
- Cystic fibrosis-associated respiratory infections
Common side effects
- Nephrotoxicity (acute kidney injury)
- Neurotoxicity (paresthesias, dizziness, vertigo)
- Neuromuscular blockade
- Fever
Key clinical trials
- Phenotypic and Genotypic Detection of Colistin Resistance
- A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (PHASE2)
- A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection
- Effect of Diluent Volume on Colistin Inhalation Therapy (NA)
- Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia (PHASE2, PHASE3)
- Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid in Colistin-Induced Nephrotoxicity (PHASE2, PHASE3)
- Therapeutic Options for CRAB (PHASE4)
- To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polymyxin e CI brief — competitive landscape report
- Polymyxin e updates RSS · CI watch RSS
- Mahmoud I Mostafa portfolio CI